Answers are grounded in this paper and cite their sources.
Review uncovers a multidimensional precision framework for pancreatic ductal adenocarcinoma, highlighting potential to overcome therapeutic resistance.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, and genome-centric precision oncology shows limited impact due to low actionable alterations and high heterogeneity. RECENT FINDINGS: A broader "Precision Pancreatic Cancer Care" (PPCC) framework integrates multi-omics, spatial biology, and patient-derived organoids to enhance early detection and functional oncology. Longitudinal molecular monitoring, microenvironment targeting, and personalized supportive care are vital to combating therapeutic resistance. CONCLUSION: Shifting from isolated genomic profiling to a multidimensional, adaptive ecosystem across the entire disease continuum holds the potential to transform PDAC management and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Okabayashi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: